Tumino Nicola, Fiore Piera Filomena, Pelosi Andrea, Moretta Lorenzo, Vacca Paola
Innate lymphoid cells Unit, Immunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Tumor Immunology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Semin Immunol. 2022 Nov;61-64:101668. doi: 10.1016/j.smim.2022.101668. Epub 2022 Nov 9.
Human myeloid-derived suppressor cells (MDSC) represent a stage of immature myeloid cells and two main subsets can be identified: monocytic and polymorphonuclear. MDSC contribute to the establishment of an immunosuppressive tumor microenvironment (TME). The presence and the activity of MDSC in patients with different tumors correlate with poor prognosis. As previously reported, MDSC promote tumor growth and use different mechanisms to suppress the immune cell-mediated anti-tumor activity. Immunosuppression mechanisms used by MDSC are broad and depend on their differentiation stage and on the pathological context. It is known that some effector cells of the immune system can play an important role in the control of tumor progression and metastatic spread. In particular, innate lymphoid cells (ILC) contribute to control tumor growth representing a potential, versatile and, immunotherapeutic tool. Despite promising results obtained by using new cellular immunotherapeutic approaches, a relevant proportion of patients do not benefit from these therapies. Novel strategies have been investigated to overcome the detrimental effect exerted by the immunosuppressive component of TME (i.e. MDSC). In this review, we summarized the characteristics and the interactions occurring between MDSC and ILC in different tumors discussing how a deeper knowledge on MDSC biology could represent an important target for tumor immunotherapy capable of decreasing immunosuppression and enhancing anti-tumor activity exerted by immune cells.
人髓系来源的抑制性细胞（MDSC）代表未成熟髓系细胞的一个阶段，可识别出两个主要亚群：单核细胞样和多形核细胞样。MDSC有助于建立免疫抑制性肿瘤微环境（TME）。不同肿瘤患者体内MDSC的存在及活性与预后不良相关。如先前报道，MDSC促进肿瘤生长，并利用不同机制抑制免疫细胞介导的抗肿瘤活性。MDSC所采用的免疫抑制机制广泛，且取决于其分化阶段和病理背景。已知免疫系统的一些效应细胞在控制肿瘤进展和转移扩散中可发挥重要作用。特别是，固有淋巴细胞（ILC）有助于控制肿瘤生长，是一种有潜力、多功能的免疫治疗工具。尽管采用新的细胞免疫治疗方法取得了令人鼓舞的结果，但仍有相当比例的患者无法从这些治疗中获益。人们已经研究了新的策略来克服TME免疫抑制成分（即MDSC）所产生的有害影响。在本综述中，我们总结了不同肿瘤中MDSC与ILC之间的特征及相互作用，探讨了对MDSC生物学的更深入了解如何能够成为肿瘤免疫治疗的一个重要靶点，从而降低免疫抑制并增强免疫细胞发挥的抗肿瘤活性。
